Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
1997
110
LTM Revenue n/a
LTM EBITDA n/a
$11.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biofrontera has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Biofrontera achieved revenue of $33.6M and an EBITDA of -$1.4M.
Biofrontera expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Biofrontera valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $26.8M | $33.6M | n/a | n/a | XXX |
Gross Profit | $25.9M | $21.9M | $27.1M | XXX | XXX |
Gross Margin | 97% | 65% | NaN% | XXX | XXX |
EBITDA | -$44.1M | -$1.4M | n/a | n/a | XXX |
EBITDA Margin | -164% | -4% | NaN% | NaN% | XXX |
Net Profit | $39.9M | -$46.0M | -$0.4M | XXX | XXX |
Net Margin | 149% | -137% | NaN% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, Biofrontera's stock price is EUR 2 (or $2).
Biofrontera has current market cap of EUR 14.0M (or $14.6M), and EV of EUR 11.4M (or $11.9M).
See Biofrontera trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$11.9M | $14.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, Biofrontera has market cap of $14.6M and EV of $11.9M.
Biofrontera's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Biofrontera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biofrontera and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $11.9M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiofrontera's NTM/LTM revenue growth is n/a
Biofrontera's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Biofrontera's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biofrontera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biofrontera and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biofrontera acquired XXX companies to date.
Last acquisition by Biofrontera was XXXXXXXX, XXXXX XXXXX XXXXXX . Biofrontera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Biofrontera founded? | Biofrontera was founded in 1997. |
Where is Biofrontera headquartered? | Biofrontera is headquartered in Germany. |
How many employees does Biofrontera have? | As of today, Biofrontera has 110 employees. |
Is Biofrontera publicy listed? | Yes, Biofrontera is a public company listed on ETR. |
What is the stock symbol of Biofrontera? | Biofrontera trades under B8FK ticker. |
When did Biofrontera go public? | Biofrontera went public in 2007. |
Who are competitors of Biofrontera? | Similar companies to Biofrontera include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Biofrontera? | Biofrontera's current market cap is $14.6M |
Is Biofrontera profitable? | Yes, Biofrontera is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.